The World Health Organization (WHO) is seeking experts to serve as members of the Strategic and Technical Advisory Group for Neglected Tropical Diseases. This “Call for Experts” notice provides information about the advisory group in question, the expert profiles being sought, the process to express interest, and the process of selection.
Background
The Strategic and Technical Advisory Group for Neglected Tropical Diseases (STAG-NTD) is the main advisory body to World Health Organization in this field.
NTDs are a diverse set of bacterial, viral, parasitic, fungal and noncommunicable diseases and disease groups that disproportionately affect populations living in poverty, predominantly in tropical and subtropical areas. Twenty diseases and disease groups are currently included in the NTD portfolio, and currently more than one billion people are affected.
STAG-NTD advises and makes policy and strategic recommendations to WHO, based on independent reviews of progress made and challenges faced by programmes and partners, with the aim of facilitating the achievement of the targets and milestones set by the NTD road map 2021–2030.
Functions of the Strategic and Technical Advisory Group for Neglected Tropical Diseases
In its capacity as an advisory body to WHO, the STAG-NTD shall have the following functions:
- To provide to WHO independent evaluation of the adequacy of progress towards the targets and milestones of the NTD road map 2021–2030;
- To review, and make recommendations to WHO for overcoming, challenges to achieving the targets and milestones of the NTD road map 2021–2030;
- To review, and make recommendations to WHO on increasing, the adoption of the three fundamental shifts in approach to tackling NTDs specified in the NTD road map 2021–2030
Operations of the Strategic and Technical Advisory Group for Neglected Tropical Diseases
The STAG-NTD will normally meet in person once a year at WHO Headquarters in Geneva, Switzerland, usually for 2-3 days. Depending on the issues at stake, additional interim meetings may be organized in the course of the year. The working language of the STAG-NTD will be English.
Who can express interest?
The STAG-NTD will be multidisciplinary, with members having a range of technical knowledge, skills and experience relevant to NTDs and of the challenges faced by programmes and partners within the context of health systems in NTD-endemic countries. Up to approximately 20 members may be selected.
WHO welcomes expressions of interest from individuals with knowledge, skills and experience in:
To register your interest in being considered for the [name of the advisory group], please submit the following documents by 24:00h (midnight) Geneva time on 16 July 2022 to aimel@who.int using the subject line “Expression of interest for the STAG-NTD”.
After submission, your expression of interest will be reviewed by WHO. Due to an expected high volume of interest, only selected individuals will be informed.
Members of WHO advisory groups (AGs) must be free of any real, potential or apparent conflicts of interest. To this end, applicants are required to complete the WHO Declaration of Interests for WHO Experts, and the selection as a member of an AG is, amongst other things, dependent on WHO determining that there is no conflict of interest or that any identified conflicts could be appropriately managed (in addition to WHO’s evaluation of an applicant’s experience, expertise and motivation and other criteria).
All AG members will serve in their individual expert capacity and shall not represent any governments, any commercial industries or entities, any research, academic or civil society organizations, or any other bodies, entities, institutions or organizations. They are expected to fully comply with the Code of Conduct for WHO Experts (https://www.who.int/about/ethics/declarations-of-interest). AG members will be expected to sign and return a completed confidentiality undertaking prior to the beginning of the first meeting.
At any point during the selection process, telephone interviews may be scheduled between an applicant and the WHO Secretariat to enable WHO to ask questions relating to the applicant’s experience and expertise and/or to assess whether the applicant meets the criteria for membership in the relevant AG.
The selection of members of the AG will be made by WHO in its sole discretion, taking into account the following (non-exclusive) criteria: relevant technical expertise; experience in international and country policy work; communication skills; and ability to work constructively with people from different cultural backgrounds and orientations .The selection of AG members will also take account of the need for diverse perspectives from different regions, especially from low and middle-income countries, and for gender balance.
If selected by WHO, proposed members will be sent an invitation letter and a Memorandum of Agreement. Appointment as a member of an AG will be subject to the proposed member returning to WHO the countersigned copy of these two documents.
WHO reserves the right to accept or reject any expression of interest, to annul the open call process and reject all expressions of interest at any time without incurring any liability to the affected applicant or applicants and without any obligation to inform the affected applicant or applicants of the grounds for WHO's action. WHO may also decide, at any time, not to proceed with the establishment of the AG, disband an existing AG or modify the work of the AG.
WHO shall not in any way be obliged to reveal, or discuss with any applicant, how an expression of interest was assessed, or to provide any other information relating to the evaluation/selection process or to state the reasons for not choosing a member.
WHO may publish the names and a short biography of the selected individuals on the WHO internet.
AG members will not be remunerated for their services in relation to the AG or otherwise. Travel and accommodation expenses of AG members to participate in AG meetings will be covered by WHO in accordance with its applicable policies, rules and procedures.
The appointment will be limited in time as indicated in the letter of appointment.
If you have any questions about this “Call for experts”, please write to aimel@who.int well before the applicable deadline.
The Stop
TB Partnership Working Group on New TB Vaccines (WGNV) and the National
Institute for Allergy and Infectious Diseases (NIAID)are
co-hosting a workshop on the topic of Recognition and Control of Mtb
Infected Cells: From Basics to the Clinic. This workshop is intended to address
the need for correlates and to identify platforms that measure recognition or
control of the infected cell - especially in humans - as identified in the EDCTP/AIGHD Global Roadmap for
Research and Development of New TB Vaccines and the Strategic Framework for
New TB Vaccines in the Stop TB Partnership Global Plan to End TB 2023 - 2030.
The overall goals of this workshop
are to:
The workshop format will be largely
discussion-based. Each session will have three short presentations that will
provide a high-level overview of key topics within the session theme, followed
by a discussion between the session chairs, speakers, and participants.
Click here
to view the programme and
speakers.
This workshop is free of charge and
open to any participants interested in this topic.
The International Society for Infectious Diseases (ISID) and the Swiss
Society for Infectious Diseases (SSI) are inviting applications for their joint
Infectious Diseases Research Fellowship Program. The purpose of this programme
is to support infectious disease physicians and scientists from under-resourced
countries through multidisciplinary clinical and laboratory training at a
select biomedical institution in Zurich, Switzerland. The one-year SSI/ISID
Fellowship programme is open to applicants who are 40 years or younger,
citizens and permanent residents of under-resourced countries or Eastern
Europe. The deadline for applications is 16 June 2023.
More information: https://na.eventscloud.com/eSites/748378/Homepage
The MRCT Center and Medable convened a multi-stakeholder task force to address ethical and regulatory opportunities and challenges related to Decentralized Clinical Trials (DCTs). Join them on June 20, from 10 - 11 AM ET, for a joint webinar entitled, "Ethical Review of Decentralized Clinical Trials (DCTs): Tools, Resources & Best Practices."
During the webinar, Barbara Bierer (MRCT Center), Pam Tenaerts
(Medable) and Leanne Madre (Medable) will present a framework, recommendations,
and tools organized around 3 DCT domains: People, Remote Data Collection, and
Data Oversight. Best practices for the ethical review, approval, and conduct of
DCTs will be provided.
Clinical trial stakeholders (IRB/ECs,
HRPP, sites, sponsors, investigators, and others) to register for the webinar here